BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20615414)

  • 1. Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy.
    Hoskins AC; Jacques A; Bardswell SC; McKenna WJ; Tsang V; dos Remedios CG; Ehler E; Adams K; Jalilzadeh S; Avkiran M; Watkins H; Redwood C; Marston SB; Kentish JC
    J Mol Cell Cardiol; 2010 Nov; 49(5):737-45. PubMed ID: 20615414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations.
    Sequeira V; Wijnker PJ; Nijenkamp LL; Kuster DW; Najafi A; Witjas-Paalberends ER; Regan JA; Boontje N; Ten Cate FJ; Germans T; Carrier L; Sadayappan S; van Slegtenhorst MA; Zaremba R; Foster DB; Murphy AM; Poggesi C; Dos Remedios C; Stienen GJ; Ho CY; Michels M; van der Velden J
    Circ Res; 2013 May; 112(11):1491-505. PubMed ID: 23508784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.
    van Dijk SJ; Paalberends ER; Najafi A; Michels M; Sadayappan S; Carrier L; Boontje NM; Kuster DW; van Slegtenhorst M; Dooijes D; dos Remedios C; ten Cate FJ; Stienen GJ; van der Velden J
    Circ Heart Fail; 2012 Jan; 5(1):36-46. PubMed ID: 22178992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy.
    Witjas-Paalberends ER; Piroddi N; Stam K; van Dijk SJ; Oliviera VS; Ferrara C; Scellini B; Hazebroek M; ten Cate FJ; van Slegtenhorst M; dos Remedios C; Niessen HW; Tesi C; Stienen GJ; Heymans S; Michels M; Poggesi C; van der Velden J
    Cardiovasc Res; 2013 Aug; 99(3):432-41. PubMed ID: 23674513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.
    Fraysse B; Weinberger F; Bardswell SC; Cuello F; Vignier N; Geertz B; Starbatty J; Krämer E; Coirault C; Eschenhagen T; Kentish JC; Avkiran M; Carrier L
    J Mol Cell Cardiol; 2012 Jun; 52(6):1299-307. PubMed ID: 22465693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel insights on the relationship between T-tubular defects and contractile dysfunction in a mouse model of hypertrophic cardiomyopathy.
    Crocini C; Ferrantini C; Scardigli M; Coppini R; Mazzoni L; Lazzeri E; Pioner JM; Scellini B; Guo A; Song LS; Yan P; Loew LM; Tardiff J; Tesi C; Vanzi F; Cerbai E; Pavone FS; Sacconi L; Poggesi C
    J Mol Cell Cardiol; 2016 Feb; 91():42-51. PubMed ID: 26714042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes.
    Wang L; Kim K; Parikh S; Cadar AG; Bersell KR; He H; Pinto JR; Kryshtal DO; Knollmann BC
    J Mol Cell Cardiol; 2018 Jan; 114():320-327. PubMed ID: 29217433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preserved cross-bridge kinetics in human hypertrophic cardiomyopathy patients with MYBPC3 mutations.
    van Dijk SJ; Boontje NM; Heymans MW; Ten Cate FJ; Michels M; Dos Remedios C; Dooijes D; van Slegtenhorst MA; van der Velden J; Stienen GJ
    Pflugers Arch; 2014 Aug; 466(8):1619-33. PubMed ID: 24186209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and functional impact of troponin C-mediated Ca
    Gonzalez-Martinez D; Johnston JR; Landim-Vieira M; Ma W; Antipova O; Awan O; Irving TC; Bryant Chase P; Pinto JR
    J Mol Cell Cardiol; 2018 Oct; 123():26-37. PubMed ID: 30138628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lys184 deletion in troponin I impairs relaxation kinetics and induces hypercontractility in murine cardiac myofibrils.
    Iorga B; Blaudeck N; Solzin J; Neulen A; Stehle I; Lopez Davila AJ; Pfitzer G; Stehle R
    Cardiovasc Res; 2008 Mar; 77(4):676-86. PubMed ID: 18096573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM.
    Piroddi N; Witjas-Paalberends ER; Ferrara C; Ferrantini C; Vitale G; Scellini B; Wijnker PJM; Sequiera V; Dooijes D; Dos Remedios C; Schlossarek S; Leung MC; Messer A; Ward DG; Biggeri A; Tesi C; Carrier L; Redwood CS; Marston SB; van der Velden J; Poggesi C
    J Gen Physiol; 2019 Jan; 151(1):18-29. PubMed ID: 30578328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation.
    Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X
    Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
    Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
    J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.
    Ferrantini C; Coppini R; Pioner JM; Gentile F; Tosi B; Mazzoni L; Scellini B; Piroddi N; Laurino A; Santini L; Spinelli V; Sacconi L; De Tombe P; Moore R; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Tesi C; Poggesi C
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28735292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.
    Tanaka A; Yuasa S; Mearini G; Egashira T; Seki T; Kodaira M; Kusumoto D; Kuroda Y; Okata S; Suzuki T; Inohara T; Arimura T; Makino S; Kimura K; Kimura A; Furukawa T; Carrier L; Node K; Fukuda K
    J Am Heart Assoc; 2014 Nov; 3(6):e001263. PubMed ID: 25389285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
    Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
    Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction.
    van Dijk SJ; Dooijes D; dos Remedios C; Michels M; Lamers JM; Winegrad S; Schlossarek S; Carrier L; ten Cate FJ; Stienen GJ; van der Velden J
    Circulation; 2009 Mar; 119(11):1473-83. PubMed ID: 19273718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
    Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
    J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human
    Pioner JM; Vitale G; Steczina S; Langione M; Margara F; Santini L; Giardini F; Lazzeri E; Piroddi N; Scellini B; Palandri C; Schuldt M; Spinelli V; Girolami F; Mazzarotto F; van der Velden J; Cerbai E; Tesi C; Olivotto I; Bueno-Orovio A; Sacconi L; Coppini R; Ferrantini C; Regnier M; Poggesi C
    Circ Res; 2023 Mar; 132(5):628-644. PubMed ID: 36744470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice.
    Najafi A; Schlossarek S; van Deel ED; van den Heuvel N; Güçlü A; Goebel M; Kuster DW; Carrier L; van der Velden J
    Pflugers Arch; 2015 Jun; 467(6):1303-17. PubMed ID: 25010737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.